Protocol #: OSU [ZIP_CODE] 
Version Date: 10/17/2024   
Page 1 of 42    
 
Local Protocol #: OSU-[ZIP_CODE] 
 Study Registry ID: [REMOVED]  FDA IND#:  143553 
 
TITLE:  A PHASE Ib STUDY  OF THE SAFETY AND PHARMACOLOGY OF 
NILOTINIB TO PREVENT PACLITAXEL -INDUCED PERIPHERAL 
NEUROPATHY IN PATIENTS WITH  BREAST CANCER  
  
Principal  Investigators: Nicole Williams, MD  
Division of Medical  
Oncology 
[ADDRESS_212030] Tower
 
Columbus, OH [ZIP_CODE]  
Tel: (614) 293 -0066 
Fax: ([PHONE_3858] 
Email: [EMAIL_3553]   
 
Shuiying Hu, PhD Pharmaceutics & Pharmacology   
[ADDRESS_212031].  
Columbus, OH [ZIP_CODE]  
Tel: ([PHONE_3859] 
Email: [EMAIL_3554] 
  
Other Agent(s): Nilotinib, Paclitaxel  
 
Protocol Type: 
Original / Version #1.0 / Version Date:  11/1/2/2018 
Version #2: 2/19/2019  
Version #3: 03/01/2019  
Version #4: 10/22/2019  
Version #5: 12/31/2019 Version #6: 04/24/2020 Version #7: 11/03/2020
 
     Version #8: 01/29/2021 
     Version #9: 08/20/2021      Version #10: 07/28/2023      Version #11: 10/17/2024  
Funding : National Cancer Institute  1R01CA238946-01 to Lustberg and Hu    04/01/2019
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 2 of 42   
Table of Contents  
 TRIAL SUMMARY & SCHEMA  ................................................................................................................. 4  
1.1 TRIAL DESIGN  ......................................................................................................................................................... 4  
1.2 STUDY SCHEMA PHASE 1B ........................................................................................................................................ 4  
 TRIAL OBJECTIVES AND ENDPOINTS  ................................................................................................ ...... 6  
2.1. Primary Objectives  ................................................................................................................................................ 6  
2.2 Secondary Objectives  ............................................................................................................................................. 6  
 BACKGROUND ................................................................................................................................ ...... 6  
3.1 CHEMOTHERAPY -INDUCED PERIPHERAL NEUROPATHY (CIPN) ................................................................................. 6  
3.2 COMPLICATIONS ASSOCIATED WITH CIPN .................................................................................................................... 7  
3.3 NEW STRATEGIES FOR PREVENTION OF CIPN:  TARGETING PACLITAXEL TOXICITY  ................................................................. 7  
3.4.1 CIPN 20 ................................................................................................................................................................ 9  
3.4.2 Other Assessments  .............................................................................................................................................. 9  
3.5 RATIONALE AND FEASIBILITY  ..................................................................................................................................... 9  
 METHODOLOGY  .................................................................................................................................. 10 
4.1 ENTRY CRITERIA  ............................................................................................................................................ 10 
4.1.1  Inclusion Criteria  ........................................................................................................................................... 10 
4.1.2 Exclusion Criteria  ............................................................................................................................................... 11 
4.2.  STUDY LOCATION AND SAMPLE  ............................................................................................................................... 12 
4.3 REGISTRATION AND STRATIFICATION  ......................................................................................................................... 12 
4.4 STUDY TREATMENT  ............................................................................................................................................... 13 
4.5 CLINICAL ASSESSMENTS .......................................................................................................................................... 13 
4.6 EVALUATION OF NEUROPATHY SYMPTOMS  ................................................................................................................ 13 
4.6.1 Patient Reported Outcomes  .............................................................................................................................. 13 
4.7 DURATION OF THERAPY  ......................................................................................................................................... 13 
4.8 DURATION OF FOLLOW UP  ......................................................................................................................................  14 
4.9 CRITERIA FOR REMOVAL FROM STUDY  ....................................................................................................................... 14 
4.10  ADHERENCE  ....................................................................................................................................................... 14 
 PHARMACEUTICAL INFORMATION ...................................................................................................... 14 
5.1 PACLITAXEL  .................................................................................................................................................. 14 
5.1.1 Adverse Events of Paclitaxel  .............................................................................................................................. 15 
Please see section 7.3 for detailed toxicities reported on paclitaxel.  ......................................................................... 15 
5.1.2 Dose and Schedule of Paclitaxel  ........................................................................................................................ 15 
5.2 NILOTINIB ............................................................................................................................................................ 15 
Please see section 7.3 for detailed toxicities reported on nilotinib. Please note that these toxicities are for 
continuous dosing of drug but in this study only intermittent dosing will be used. Therefore, anticipated toxicity is 
expected to be much less.  .......................................................................................................................................... 15 
 POTENTIAL TOXICITY, DOSE MODIFICATIONS, AND MANAGEMENT  ..................................................... 16 
6.1 ASSESSMENT OF DOSE LIMITING TOXICITIES  ............................................................................................................... 18 
 TREATMENT PLAN  ............................................................................................................................... 20 
7.1 TREATMENT PLAN AND OVERVIEW  ........................................................................................................................... 20 
7.2 STUDY CALENDAR  ................................................................................................................................................. 21 
Study Calendar Phase Ib  - Schedule A (weekly paclitaxel)  
Study Calendar Phase Ib  - Schedule B (dose dense paclitaxel) 
*PLEASE SEE SECTION 8.1 FOR DETAILED PK SCHEDULE  ...................................................................................................... 22 
*PLEASE SEE SECTION 8.1 FOR DETAILED PK SCHEDULE  ...................................................................................................... 23 
7.3  ADVERSE EVENTS ASSOCIATED WITH NILOTINIB AND PACLITAXEL  .................................................................................. 24 
7.3.1 Adverse Events Reported on Nilotinib Trials  ..................................................................................................... 24 
7.3.2 Adverse Events Reported for Paclitaxel  .............................................................................................................  25 
 CORRELATIVE STUDIES  ........................................................................................................................ 27 
8.1 INTEGRATED CORRELATIVE STUDIES : PK OF NILOTINIB AND PACLITAXEL  .......................................................................... 28 
8.2 INTEGRATED CORRELATIVE STUDIES : BIOMARKERS OF OATP1B1  .................................................................................. 30 
 ADVERSE EVENT REPORTING  ............................................................................................................... 31 
9.1 ATTRIBUTION OF THE ADVERSE EVENTS  ..................................................................................................................... 31 
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 3 of 42  9.2 DOCUMENTATION  ................................................................................................................................................. 32 
9.3 REPORTING  .......................................................................................................................................................... 32 
 DATA REPORTING / REGULATORY REQUIREMENTS  ............................................................................. [ADDRESS_212032]  ............................................................................................................................. 32 
10.3  INFORMED CONSENT  ........................................................................................................................................... 33 
10.4  PATIENT CONFIDENTIALITY  .................................................................................................................................... 33 
10.5  PUBLICATION AND RESEARCH FINDINGS  .................................................................................................................. 33 
10.6  COMPLIANCE MONITORING  .................................................................................................................................. 33 
10.7  DATA SAFETY MONITORING  .................................................................................................................................. 33 
10.8  RESPONSIBILITY FOR DATA SUBMISSION  .................................................................................................................. 34 
10.9  DATA AND RECORDS  ............................................................................................................................................ 34 
10.10  SAFETY AND MONITORING  .................................................................................................................................. 34 
10.11  ACCOUNTABILITY  .............................................................................................................................................. 34 
10.12  DOCUMENTATION  ............................................................................................................................................ 34 
10.13  REPORTING  ...................................................................................................................................................... 35 
 STATISTICAL CONSIDERATIONS ........................................................................................................... 36 
11.1  STUDY ENDPOINTS  .............................................................................................................................................. 36 
DEFINITION OF PRIMARY ENDPOINT  ............................................................................................................................... 36 
• SAFETY , TOLERABILITY AND RP2D  OF NILOTINIB IN COMBINATION WITH PACLITAXEL . ...................................................... 36 
DEFINITION OF SECONDARY ENDPOINTS  .......................................................................................................................... 36 
11.2  STUDY DESIGN AND SAMPLE SIZE CALCULATION  ....................................................................................................... 37 
11.3  STATISTICAL DATA ANALYSIS  ................................................................................................................................. 38 
 REFERENCES  ....................................................................................................................................... 39 
 
  
  
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 4 of 42   
 TRIAL SUMMARY & SCHEMA 
 
Abbreviated Title  PHASE Ib STUDY  OF SAFETY AND 
PHARMACOLOGY OF NILOTINIB TO 
PREVENT PACLITAXEL- INDUCED 
PERIPHERAL NEUROPATHY  
Trial Phase  Ib 
Clinical Indication  Stages I -III Breast Cancer  
Trial Type  Single arm Phase 1b  
Type of control  None  
Route of 
administration  Oral nilotinib  
IV paclitaxel  
Trial Blinding  None  
Treatment Groups  All study subjects will receive nilotinib.  
Number of trial 
subjects Approximately up to [ADDRESS_212033] cancer who are initiating 
chemotherapy with paclitaxel. Intermittent doses of nilotinib will be administered (Day -
1 to Day 1; each dose administered with paclitaxel except cycle 1 day 1 ). Nilotinib will 
be administered orally once a day 24 hours before each paclitaxel infusion (excluding 
cycle 1 day 1) and then repeated approximately 30 minutes prior to paclitaxel infusion 
to evaluate DLTs, MTD, or MAD.  
 
 
1.2 Study Schema  Phase 1b 
 
There are two paclitaxel dosing schedules administered in the clinic based on investigator discretion – either weekly paclitaxel or dose-dense paclitaxel given every two weeks. The study schemas below describe the interventions for the two dosing schedules.  
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 5 of 42    
Schedule A:  
• weekly dose of 80mg/m2, paclitaxel will be given weekly on days 1, 8, 15, of every 
21 days.  
• Nilotinib will be given orally on cycle 1 Days 7, 8, 14, 15 once a day 24 hours 
prior to the paclitaxel infusion and again 30 minutes prior to the paclitaxel infusion on days 8, 15.  
• During the cycle 1, PK will be obtained at baseline, during, and up to 6 hours after paclitaxel or nilotinib administration on the days shown above. 
• Patients will continue paclitaxel without nilotinib after cycle [ADDRESS_212034] of care at the discretion of the treating investigator.  
  
 
 
 
 Schedule B:  
• For dose dense schedule of 175mg/m2, paclitaxel will be given once every two weeks on 

Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 6 of 42  day 1.   
• Nilotinib will be given orally on cycle 1 Days 14, once a day 24 hours prior to the cycle 
2 paclitaxel infusion and again 30 minutes prior to the paclitaxel infusion on day 1.    
• During the cycle 1 & 2, PK will be obtained at baseline, during, and up to 6 hours after paclitaxel or nilotinib administration on the days shown above. 
• Patients will continue paclitaxel without nilotinib after cycle [ADDRESS_212035] of care 
at the discretion of the treating investigator.  
 
 TRIAL OBJECTIVES  AND ENDPOINTS  
 
2.1. Primary Objectives  
(1) To determine the recommended phase 2 dose (RP2D) of nilotinib in combination with paclitaxel for early stage breast cancer, defined as the lowest 
intermittent dose of nilotinib  that can temporarily inhibit the function of OATP1B1 
without affecting the plasma pharmacokinetics of paclitaxel . 
(2) To determine the toxicity profile (based on CTCAE v. 5.0) of nilotinib in combination with paclitaxel in early stage breast cancer patients.  
 2.2 Secondary Objectives  
(1) To determine  the effect  of paclitaxel on  PK of nilotinib  in the study population. 
To determine  the effect  of nilotinib  on PK of paclitaxel  in the study population. 
 
2.3  Exploratory Objectives:  
(1)   To evaluate quality of life  and chemotherapy induced neuropathy symptoms 
using the CIPN20 questionnaire (2)   To determine the disease- free survival (DFS), event free survival (EFS) and   
overall survival (OS) of nilotinib in combination with paclitaxel.  
 
 
 
 BACKGROUND  
 
3.1 Chemotherapy -Induced P eripheral N europathy (CIPN)  
 
Breast cancer detection and treatment has improved significantly in recent years,  with breast 
cancer patients currently comprising the largest groups of cancer survivors. However, more than 
30% of patients receiving chemotherapy experience  chemotherapy -induced peripheral 
neuropathy (CIPN), which occurs  as a result of several commonly used classes of chemotherapy 
drugs including taxanes, vinca alkaloids and platinum compounds. CIPN is predominantly a sensory neuropathy with symptoms of paresthesia and pain, but also includes a component of motor neuropathy. In many populations including the elderly and diabetics, as well as cancer patients, CIPN is also associated with not only pain, but also with falls  and difficulty in walking 
and performing activities of daily living (ADLs).
1-[ADDRESS_212036] for years, and for some patients, full reversibility of 
symptoms may never occur. In addition to peripheral nervous system impairments, c hemotherapy 
treatment is also associated with central nervous system impairments, including detrimental 
changes to blood flow in frontal lobes of the brain, w hich are important for motivation and 
neurocogni tion, as well as in brain areas responsible for processing pain. Comb ined, these nervous 
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 7 of 42  system changes induced by [CONTACT_180253]. 
 
3.2 Complications associated with CIPN 
 
Among the taxanes, the drug paclitaxel is associated with an acute pai n syndrome, known as 
paclitaxel -associated pain syndrome (P -APS). This syndrome occurs within [ADDRESS_212037] patients’ progress . Preventative and therapeutic interventions have been 
attempted  but have had limited success or have produced additional toxicity. To date, no 
preventative strategy for  CIPN has been confirmed by [CONTACT_180254]. A 
recent ly reported study with duloxetine as treatment for CIPN was promising .5 Improved 
understanding of the pathophysiology of CIPN would help in the rational design of studies for the 
prevention and treatment of this very common cytotoxicity.  
 
3.3 New S trategies for P revention of CIPN : Targeting P aclitaxel T oxicity  
 
To date, more than [ADDRESS_212038] been limited by [CONTACT_180255] a firm mechanistic rationale. T he translational exploration of 
many of the proposed intervention 
strategies has been hampered by [CONTACT_180256] ( i) paclitaxel has multiple 
intracellular targets , hence blocking a 
single injurious event will only have partial protective effects; and ( ii) the 
protective approach may diminish the antitumor effects of paclitaxel given the potential overlap in cell death signaling pathways between normal cells and tumor 
cells. Therefore, an optimal approach is to simultaneously protect the peripheral nerves against toxicity from paclitaxel 
without affecting its therapeutic effects in 
tumors. The development of such an 
approach would rely on the identification of the cri tical differences between normal and malignant 
cells that drive toxic responses to paclitaxel. We recently found that paclitaxel accumulates in cells through a process mediated by [CONTACT_180257]1B2 (OATP1B1 and OATP1B3 in humans; Fig 1 ).
7 We also found that paclitaxel induces acute and 
chronic forms of neurotoxicity in mice in an OATP1B2- dependent manner, and that these 
phenotypes can be completely reversed by [CONTACT_094] -treatment with the tyrosine kinase inhibitor (TKI) 
nilotinib ( Fig 2 ).7 
Figure 1.  Dependence of acute paclitaxel -induced peripheral neuropathy on 
OATP1B2.  (A) Plasma levels of paclitaxel in wild- type and OATP1B2( -/-) mice (n=4); 
(B)  Mechanical allodynia as determined by a Von Frey Hairs test (n=8). Data present 
mean ± SE after one ( A) or 2 (B) doses of paclitaxel (10 mg/kg, i.v.; time 0 and 72 h). The 
star (*) denotes significant differences from baseline and OATP1B2( -/-) mice (P<0.01).  
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/[ADDRESS_212039] detailed, below, additional data that 
supports that the proposed once a day doses of nilotinib 
are lower than currently  approved labeling doses for this 
drug, are safe, and do not increase paclitaxel toxicity (Please see section 3.6) .
    In order to assess the degree of 
OATP1B1 inhibition by [CONTACT_180258], analysis of glycochenodeoxycholate sulfate (GCDGA -S) and 
chenodeoxycholate-24- glucuronide (CDCA -24G) levels 
will be performed in plasma samples as validated surrogate endogenous substrates of OATP1B1. Previous clinical studies have indicated that the area under the curve ( AUC ) of GCDCA- S can be 
increased >[ADDRESS_212040] that the administration of nilotinib will result in dose -dependent changes in levels of 
GCDAGA- S and CDCA -24G caused by [CONTACT_180259]1B1. Since the initial approval of the 
protocol, significant progress has been made in the identification of other endogenous biomarkers 
to assess the OATP1B transporter function. With rich clinical datasets, e merging evidence 
suggests that  coproporphyrin- I (CP -I) and coproporphyrin -III (CP[INVESTIGATOR_51381]I),  compounds formed in the 
body as by[CONTACT_180260], have higher selectivity and sensitivity and can be used to 
better assess in vivo OATP1B1 activity.10-12 Furthermore, we recently identified α -tocopherol as 
a DRG- specific OATP1B -type transporter biomarker that can be measured in the circulation13, 
analysis of additional biomarker CP -I, CPI[INVESTIGATOR_180229] α-tocopherol could provide more accurate 
assessment of OATP1B1 transporter activity with nilotinib, which could serve as a companion diagnostic to guide dose selection of pharmacological inhibitors in the future development of combinatorial regimens with  chemotherapy drugs.  
Although combining paclitaxel with nilotinib could possibly reduce the incidence and 
severity of neuropathy, it is important to establish that the anticancer efficacy  of paclitaxel  is not 
compromised by [CONTACT_180258]. We already confirmed that the OATP1B1 and OATP1B3 genes are expressed at low levels in MBC samples and that the cellular uptake and cytotoxicity of paclitaxel are not reduced by [CONTACT_180261].
7 In addition, the nilotinib- paclitaxel combination 
was recently identified as a synergistic drug pair in vivo , resulting in tumor regressions in a MBC 
xenograft model , with no tumor regrowth observed for more than 80 days following the end of 
therapy.14 Although in vivo  confirmation is required in patient -derived xenograft models that more 
faithfully represent the characteristics of primary human MBC ,15 these initial observations 
indicate that combining paclitaxel with nilotinib has the potential to simultaneously reduce 
toxicities and increase anticancer effects. 
 
3.4. Measuring CIPN  
Patient reported outcomes (PRO) are the gold standard for evaluation of CIPN symptoms. 
Figure 2.  Proposed model of paclitaxel -induced injury to 
the peripheral nervous system. Paclitaxel enters the 
nervous system through OATP1B2, ultimately leading to 
peripheral neuropathy (top). These effects can be blocked 
by [CONTACT_180262]1B2 inhibitor nilotinib (bottom).  
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/[ADDRESS_212041] been evaluated in large scale studies. For the purposes of this 
study, CIPN-20 will be used.16 
 3.4.1 CIPN 20  
 
CIPN 20 is a validated instrument for longitudinal evaluation of neuropathy symptoms induced by [CONTACT_11553]. This 20- item self- report questionnaire includes three subscales 
evaluating sensory, motor and autonomic symptoms. It is easy to use and is completed by [CONTACT_180263]. This instrument was designed and validated to evaluate patients’ symptoms of CIPN during chemotherapy treatment with a number of chemotherapeutic agents, including taxanes.
[ADDRESS_212042], submitted International Conference on Molecular Targets and Cancer Therapeutics the preliminary data from the 
ongoing study at NCI (Clinicaltrials.gov ID [STUDY_ID_REMOVED]) patients with solid tumors (n=30) treated for up to 41 cycles with weekly paclitaxel and twice daily nilotinib. The MTD was 80 mg/m2 paclitaxel and nilotinib [ADDRESS_212043] terminated study protocol due to toxicity. Preliminary response data are promising, especially considering the PRs observed in pts who had previously been unresponsive to paclitaxel therapy.  Of the 24 pts assessable for response to date, there are 4 confirmed partial responses (PRs; 17%, 1 pt with endometrial cancer, 1 pt with anal cancer and 2 pts with granulosa cell of the ovary) and [ADDRESS_212044] response of stable disease (SD; 50%), including 6 pts with SD for ≥8 cycles. Mean time on study to date is 8.7 months (range: 2 – 41 months). Three of [ADDRESS_212045] response of only SD (1 pt) or progressive disease (2 pts) to carboplatin/paclitaxel or paclitaxel monotherapy, respectively.  Preliminary results from [STUDY_ID_REMOVED] are described below in Table 1. 
 
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 10 of 42  Table 1. Preliminary Data from [STUDY_ID_REMOVED] 
Condition  Number of Patients  
Paclitaxel Dose Delays due to Myelosuppression  0 
Paclitaxel Dose Delays due to QTC Elongation  0 
Termination from Study due to Toxicity  0 
Partial Responses to Paclitaxel after Prior Unresponsiveness  4 (of the 24 with available data)  
Maintained Stable Disease  12 (of the 24 with available data)  
*[ADDRESS_212046]  cancer  stages I -III 
2. Be e ligible for weekly  or dose dense single agent  paclitaxel therapy  based on 
physician assessment  
3. Be ≥[ADDRESS_212047] an ECOG performance status ≤ 2  
 Patients with ECOG scores of 3 or greater typi[INVESTIGATOR_180230]  
5. Demonstrate adequate organ and marrow function as defined in Table 2. 
 
Table 2. Adequate Organ and Marrow laboratory values 
 Laboratory values  
Leukocytes  ≥ 2,000/µL  
Absolute  neutrophil  count  ≥ 1,500/µL  
Platelets  ≥ 100,000/µL  
Total bilirubin  ≤ UNL  
AST  (SGOT)/ALT  (SGPT)  ≤ 2.5 × I nstitutional upper limit of 
normal*   
 Data collected from 30 patients with solid tumors treated with up to 41 cycles of weekly paclitaxel and twice daily 
with nilotinib. MTD = 80mg/m2 paclitaxel and 300 mg nilotinib bid. Mean time on study is 8.7 months (2 -41). 
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 11 of 42  Creatinine  Within normal  institutional  limits  OR  
≥50mL/min for patients  with 
creatinine  levels above institutional 
normal.  
QTc <[ADDRESS_212048] agree to use adequate  
contraception prior to  study entry, for the duration of study participation  and for 
3 months after completion of study treatment administration. Adequate 
contraception includes methods such as oral contraceptives, double barrier 
method (condom plus spermicide or diaphragm), or abstaining from sexual  
intercourse.  
8. Be willing and able  to understand and sign the written  informed  consent 
document. 
9. Demonstrate adequate electrolyte values as defined below. Hypokalemia and/or 
hypomagnesemia must be corrected prior to initiating nilotinib:  
 Calcium 8.6-10.5mg/dL 
 Magnesium 1.6-2.6mg/dL 
 
4.1.2 Exclusion C riteria  
 
1. Known distant metastatic disease  
2. Is HER2+ and is receiving paclitaxel in conjunction with trastuzumab +/- pertuzumab  
3. Has experienced > grade [ADDRESS_212049] not recovered to 
grade 1 or less (except for  alopecia).  
5. Has a history  of grade 3-4 immediate  hypersensitivity reaction  to paclitaxel.  
6. Has a h istory of clinically significant allergic reactions attributed to compounds 
of similar chemical or biologic composition  to nilotinib or paclitaxel.  
7. Has uncontrolled intercurrent illness including, but not limited to, ongoing or 
active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social  situations that would limit  
compliance with study requirements.  
8. Is currently pregnant  or breast feeding as there is an unknown but potential risk 
for adverse events in nursing infants secondary to treatment of the mother with nilotinib and paclitaxel . 
9. Has any other medical or psychiatric condition that in the opi[INVESTIGATOR_180231]. 
10. Has gastrointestinal (GI) disorders  or impairment of GI function that is likely to 
significantly alter the absorption of nilotinib  
11. Has a marked baseline abnormal heart rhythm such as prolongation of QT/QTc 
interval (e.g., repeated demonstration of a QTc of > 450msec)  
12. Has a history of additional risk factors for TdP (e.g., heart failure, hypokalemia, 
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 12 of 42  hypomagnesemia , family history of Long QT Syndrome)  
13. Us e s potent CYP3A4 inhibitors (grapefruit juice, cyclosporine, ketoconazole, 
ritonavir) and if treatment cannot be either safely discontinued or switched to a 
different medication prior to starting nilotinib.  
14. Has a k nown diagnosis of HIV and is currently taking combination antiretroviral 
therapy known or suspected to affect paclitaxel PK. 
15. Is concurrently using potent OATP1B1 inhibitors, including antibiotics 
(rifampi[INVESTIGATOR_2513], rifamycin SV, systemic  fusidic acid, clarithromycin, erythromycin, 
roxithromycin, telithromycin), antiretrovirals (indinavir, saquinavir, ritonavir), 
cyclosporine, and gemfibrozil. 
 Please note: Anthracycline regimens are often used sequentially with paclitaxel based regimens in breast cancer. However, whether anthracyclines are used prior or after paclitaxel treatment has not been shown to significantly impact outcomes. Prior exposure to anthracyclines or subsequent anthracyclines should not impact our study. Therefore, any patient who meets the above eligibility criteria and is receiving single dose paclitaxel over the  duration of the present 
study is still eligible, regardless of pr ior anthracycline regimens.  
 
4.2. S tudy Location and S ample  
 
This study will be open for accrual at the Stefanie  Spi[INVESTIGATOR_180232] , part of The Ohio State University Comprehensive Cancer Center . Patient eligibility 
will be determined according to the eligibility criteria listed. The study w ill enroll up to 
approximately up to [ADDRESS_212050] be completed by [CONTACT_9137]: (1) Patient Consent Form - signed (2) Patient HIPAA Authorization Form - signed (3) Consent Documentation Note (4) Eligibility Checklist - completed & signed  
(5) Source documents verifying every inclusion & exclusion criteria. Note: Every inclusion and exclusion criteria must be documented in the patient’s medical record (emails or other notes 
outside the medical record will not be considered source documentati on) 
(6) Results from baseline tests required per the Study Calendar.  
(7) Registration Form - completed  
Upon receipt of all required registration documents and upon verification the patient meets all eligibility criteria, the study coordinator will:  
• Assign the patient a study sequence ID.  
• Register the patient on the study.  
Following registration, patients should begin protocol treatment within 14 business days. Issues that would cause treatment delays should be discussed with the Principal Investigator [INVESTIGATOR_91394]. If a patient does not receive protocol therapy following registration, the patient’s registration on the study may be canceled, after discussion with the Principal Investigator [INVESTIGATOR_32528].   All the patients enrolled in this study will receive nilotinib.  
 
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 13 of 42  4.4 S tudy  Treatment  
 
In Schedule A (weekly paclitaxel), t he starting dose of nilotinib will be 100mg p.o. once per 
day on 2 occasions 24hrs before and 30 min before paclitaxel on C1D7, C1D8, C1D14, 
C1D15.  P aclitaxel will be given at 80 mg/m2 throughout all dose levels (unless dose reduction 
is needed for other clinically standard criteria). In Schedule B (dose dense paclitaxel), nilotnib 
will be given as 100mg p.o. once per day on two occasions 24hrs before and 30min before 
paclitaxel on  C1D14 and C2D1. Duration of paclitaxel  for both schedules  is for [ADDRESS_212051] regimen and followed the package inser t and 
institutional guidelines for its administration and management of hypersensitive reactions (both acutely and for subsequent doses) will be followed (Section 1.2 study schema ).  
 
4.5 Clinical Assessments 
 
Participants will be evaluated for toxicity at baseline and on D1 of each cycle as part of clinic 
visit. In addition, clinical research coordinator will evaluate patients as part of a research encounter prior to each infusion. Toxicity evaluation of neuropathy will be recorded based on 
CTCAE  criteria v. 5 for sensory and motor neuropathy in addition to CIPN 20. 
 
4.6 Evaluation of N europathy S ymptoms  
 
4.6.1 Patient Reported Outcomes 
Patient reported outcomes (PRO) are the gold standard for evaluation of CIPN symptoms. Multiple validated instruments have been evaluated in large scale studies. For the purposes of this 
study, CIPN -[ADDRESS_212052] a diary to report daily changes in 
symptoms. Changes in the chemotherapy dosing, dose delays, discontinuation of therapy, and the amount of analgesic use during the study period will also be recorded by [CONTACT_164254].  
4.7 Duration of Therapy  
 
In Schedule A (weekly paclitaxel), nilotinib will be given only on C1D7, C1D8, C1D14, C1D15. Patients will remain on study until C4D21 of paclitaxel (unless they come off due to progression of disease) for the purpose of monitoring for the occurrence of neuropathy as defined by [CONTACT_4652] V5 and data on quality of life using CIPN20 questionnaire. In Schedule B (dose dense 
paclitaxel), nilotnib will be given on C1D14 and C2D1 only. Patient will remain on study until Cycle 4 Day 1. Further continuation of pacl itaxel will be at the discretion of the treating 
investigator. In the absence of treatment delays due to adverse event(s),  patient will stay on study  
until one of the following criteria applies:  
 
• Therapy completion,  
• Disease progression,  
• Intercurrent illness that prevents further administration of treatment,  
• Unacceptable adverse event(s),  
• Patient decides to withdraw from the study, or  
• General or specific changes in the patient's condition render the patient unacceptable for further treatment in the judgment of the investigator  
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 14 of 42  4.8 Duration of Follow up 
 
Patient s will be followed 3 months and 6 months  after completion of paclitaxel. Patients removed 
from study for unacceptable adverse event(s) will be followed until resolution or stabilization of 
the adverse event.  
 
4.9 Criteria for Removal from Study  
 
The following criteria will be used for removal of patients from the study: (1) patient withdraws 
their participation; (2) patient has a disease progression or dies (whichever occurs first);  (3) the 
study is terminated by  [CONTACT_079]; ( 4) patient develops neuropathy or other 
condition that prohibits continued treatment with paclitaxel ; (5) pregnancy or failure to practice 
appropriate contraception. The reason for study removal and the date the patient is  removed must 
be documented in the Case Report Form.  
 
4.[ADDRESS_212053] leftover pi[INVESTIGATOR_3353]. 
 
 
 PHARMACEUTICAL INFORMATION  
 
5.1 Paclitaxel   
 
Taxanes (including paclitaxel, docetaxel and nab -paclitaxel) are among the most active cytotoxic 
agents for the treatment of breast cancer.18-20 Paclitaxel was originally isolated from the bark of 
the Pacific yew tree (taxus brevifolia) and subsequently found to have anti -tumor properties in the 
early 1970s .21, [ADDRESS_212054].23 Paclitaxel is hydrophobic 
and has poor solubility in water. Therefore , this agent is solubilized in 50% polyoxyethylated 
castor oil (Cremophor EL) and 50% ethanol. Cremaphor EL vehicle is associated with 
hypersensitivity reactions which require premedication with corticosteroids and histamine receptor blockers to minimize it s incidence and severity .
[ADDRESS_212055] 2 treatments .25 
 Paclitaxel administered intravenously at a dose of 175 mg/m
[ADDRESS_212056] cancer with 
associated response rates around 30 -40% and survival of about [ADDRESS_212057] cancer .18, 26 Since the activity of paclitaxel is directly related to the 
cell cycle, shortening the interval between treatments might improve efficacy .27 In addition, 
paclitaxel administered in a more continuous manner exhibits pro- apoptotic and antiangiogenic 
properties, increasing its antineoplastic effects.28 Indeed, subsequent randomized studies 
confirmed that weekly paclitaxel administration at 80mg/m2 was superior to every -3-week 
schedul es in treatment of early stage  and operable breast cancer .29-[ADDRESS_212058] 
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 15 of 42  doubled the time to progression and increased the response rate from 29% to 42% without 
affecting quality of life in patients with stages I -III breast cancer .29 Additionally, dose dense 
paclitaxel at 175 mg/m2 has also been shown to be an effective regimen in breast cancer.[ADDRESS_212059] weekly  80 mg/m2 
paclitaxel dose schedule or the 175 mg/m2 dose dense paclitaxel every two weeks dose schedule . 
The information on the safety profile of the combination and effect of nilo tinib pharmacokinetics 
of paclitaxel will be collected in this trial.  
 
5.2 N ilotinib  
 
Nilotinib (TasignaR) will be pur chased in doses s pecified. Nilotinib is indicated for the treatment 
of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed 
Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. For 
CML, Nilotinib is taken twice  daily at approximately 12- hour intervals and must be taken on an 
empty stomach. No food should be consumed for at least [ADDRESS_212060] 1 hour after the dose is taken.  Please note this is not the dosing recommended for this 
proposal and we are proposing once daily intermittent dosing.  
 
5.2.1 Adverse Events of Nilotinib  
 
Please see section 7. 3 for detailed toxicities reported on nilotinib. Please note that these toxicities 
are for continuous dosing of drug but in this study only intermittent dosing will be used. Therefore , 
anticipated toxicity is expected to be much less.  
 
5.2.2 Dose and Schedule of Nilotinib  
 
The recommended dose of nilotinib in CML  is 300 mg orally twice daily.  However , in this study  
nilotinib will be administered p.o. once per day on 2 occasions 24hrs before and 30 min before 
paclitaxel on unless DLT encountered. A total of up to 4 nilotinib dose levels will be considered; 
50, 100, 200, and 300mg in the phase I b portion of the trial ( Tables 3a and 3b ). The maximum 
sample size will be [ADDRESS_212061] cohort of patients will be enrolled at dose 
level 1 (nilotinib 100 mg). After each cohort is treated and evaluated for toxicity and efficacy as 
defined in the context of this trial, these data will inform our dynamic, adaptive model to determine dose escalation decisions based on changes to estimated probabilities for toxicity  and 
for efficacy given the data observed. Then next cohort of patients will be treated on the dose level determined from the Bayesian adaptive model.  
 
Nilotinib must be taken on an empty stomach and no food should be consumed for at least [ADDRESS_212062] 1 hour after the dose is taken.  
All participants in the study will be advised of this.  
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 16 of 42   
5.3  Paclitaxel and nilotinib interactions 
 
Based on the NCI data Clinicaltrials.gov ID [STUDY_ID_REMOVED], the risk of myelosuppression and dos
e delays with our regimen of intermittent nilotinib dosing is expected to be unlikely. Based on 
our recent preclinical experience of nilotinib given in combination  with paclitaxel, we anticipate 
that nilotinib will not affect the disposition profile of paclitaxel and vice versa. The expectation that nilotinib is unlikely to influence the pharmacokinetics of paclitaxel would be consistent with previously reported studies confirming that other OATP1B1- inhibiting TKIs identified from our 
screens, such as axitinib, and sorafenib, do not alter the systemic exposure to paclitaxel. The above noted NCI study confirmed our preclinical anticipation, there were no observed adve rse PK 
interactions between nilotinib and paclitaxel. Although the drug- drug interaction in a clinical 
setting is highly unlikely, we will perform real -time PK analyses for both paclitaxel, nilotinib and 
in combination for parent and metabolites.  
 
 
 POTENTIAL TOXICITY, DOSE MODIFICATIONS, AND MANAGEMENT  
 
Toxicity will be monitored during study visits and telephone calls using the National Cancer In
stitute Common Terminology Criteria for Adverse Events v ersion  5.0 (CTCAE) of the National 
Cancer Institute will be used : 
(https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_
Reference_5x7.pdf ). Any Grade 1 or greater  toxicities will be reported as adverse events.  
 
Patients with any Grade ≥ 3 adverse reactions or with an absolute QTc≥ 500msec,or increase 
of baseline QTc of > 60msec during the first cycle  will count toward DLT determination . If a 
patient has a DLT, nilotinib will be stopped and paclitaxel will be c ontinued per treating 
physician. See Section 6.1 for the definition of DLTs.   
 
Table 3a. Phase 1b dose modifications for nilotinib and paclitaxel 
during cycle 1  – Schedule A (weekly paclitaxel)  
 
Dose Level  Nilotinib  
(Refer to study schema)  Weekly Paclitaxel  
(mg/m2 IV on days 1, 
8, 15)  
Level -1 50 mg  
 
(one 50 mg capsule once 
daily 24 hours before and 
day of paclitaxel 
treatment )  80 
Level 1  
 
(Starting dose 
level)  100 mg  
 
(two 50 mg capsules once 
daily 24 hours before and 
day of paclitaxel 
treatment ) 80 
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 17 of 42  Level 2  200mg  
 
 (four 50mg capsules once 
daily 24 hours before and 
day of Paclitaxel 
treatment)  80 
Level 3  300mg  
 
(six 50mg capsules once daily 24 hours before and day of paclitaxel 
treatment)  80 
   
 
  
 
Table 3b . Phase 1b dose modifications for nilotinib and paclitaxel during 
cycle 1  – Schedule B (dose dense paclitaxel)  
   
Dose Level  Nilotinib  
(Refer to study schema)  Dose dense  
Paclitaxel  
(mg/m2 IV)  
Level -1 50 mg  
 
(one 50 mg capsule once 
daily 24 hours before and day of paclitaxel 
treatment  175 
Level 1  
 (Starting dose 
level)  100 mg  
 
(two 50 mg capsules 
once daily 24 hours 
before and day of 
paclitaxel treatment  175 
Level 2  200mg  
 
 (four 50mg capsules 
once daily 24 hours 
before and day of 
Paclitaxel treatment)  175 
Level 3  300mg  
 
(six 50mg capsules once daily 24 hours before and day of paclitaxel 
treatment  )  175 
 
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 18 of 42  We do not anticipate significant ly increased toxicities given intermittent dosing of drug  and 
administration of drug nilotinib only during cycles 1 and 2, if using the dose dense schedule, and 
excellent tolerability and lack of myelosuppression with continuous dosing noted in Clinicaltrials.gov ID [STUDY_ID_REMOVED].   Dose levels  for phase I b will follow Table s 3a and 3b.  Movement across these levels will be per 
statistical models as outlined in section 11.2   Nilotinib is started at dose level 1.  Dose escalations and de -escalations will be based on the 
observed dose limiting toxicities and efficacy ( OATP1B1 inhibition) of the patients who have 
been treated as described in section  11.2.  
 
Dose modification after cycle 1  (and cycle 2 for the dose dense schedule)  for paclitaxel will be 
left up to treating physician discretion since patients are no longer on nilotinib.   
 
N
ote: In order to receive weekly paclitaxel during cycle [ADDRESS_212063] be met:  
 
• ANC ≥ 1000/μL  
• Platelets ≥ 75,000/μL  
• No grade [ADDRESS_212064] be met:  
 
• Calcium ≥8.6mg/dL 
• Magnesium ≥1.6.dL 
 If these criteria are not met, treatment must be delayed until toxicity is improved to grade 2 or better. Hypokalemia and/or hypomagnesemia must be corrected prior to initiating nilotinib. 
Filgrastim may not be used during cycle [ADDRESS_212065] of c are pegfilgastrim will be used to maintain adequate blood counts per 
routine care practice.  
 For any grade ≥  2 QTC prolongation or any grade ≥  2 cardiac event, nilotinib should be held as 
per the [LOCATION_002] Prescribing Information for nilotinib, and cardiology should be consulted prior to restarting the patient on nilotinib.  
  
6.1 Assessment of Dose Limiting Toxicities  
 
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/[ADDRESS_212066] cycle  for schedule A and the second 
cycle during schedule B; thus, toxicities observed during the specified DLT period of treatment 
will be used to direct decisions related to dose escalation and ultimately to determine the RP2D. 
Patients  who do not complete the first cycle  for schedule A and cycle  1 and 2 for schedule B of 
combination treatment for reasons other than toxicity or other treatment- related reasons will not 
be considered evaluable for DLT and will be replaced with another patient at that dose level.    
 Grading of toxicities will be assessed by [CONTACT_180264] (CTCAE) version 5.0. DLTs will consist of any adverse events that are at least possibly 
attributed to nilotinib in the first cycle of phase Ib  schedule A and in cycle 2 for schedule B  and are 
further defined as  follows:  
We acknowledge that the toxicities due to nilotinib and paclitaxel can be similar and any possible attribution to nilotinib will count toward DLT determination if it fits definitions below. Further, if the adverse event is not a known toxicity specific to paclitaxel and is felt to be at least possibly related to treatment, we will conservatively attribute it as possibly related to nilotinib. All adverse 
events of the specified grades will count as DLTs except those that are clearly and incontrovertibly due to disease progression or extraneous causes.  
 Hematologic DLTs 
• Grade 4 neutropenia  
• Grade ≥  3 neutropenia, complicated by   a fever  
• Grade 4  thrombocytopenia 
• Grade 3 thrombocytopenia, 
complicated by  [CONTACT_180265]-h ematologic  DLTs  
• Any CTCAE  version 5.0 Grade ≥  3 non- hematologic toxicity, unless 
the event is clearly unrelated to treatment  -- EXCEPT the  following : 
– Grade ≥ 3 nausea, vomiting, or diarrhea that resolves to Grade ≤2 
within 48 hours, with or without  medical  intervention  or prophylaxis. 
– Grade  ≥ 3 fatigue  lasting for 1 week or longer . 
– Transient (<  14 days) increase in LFTs (of ≤ 1 Grade in severity) 
compared to baseline levels in patients  with baseline liver metastases.  
– Grade  3 maculopapular rash for which  symptoms are easily  managed  
with supportive care and  no evidence of superinfection or limitation  
of self-care ADLs.  
– Grade ≥ 3 electrolyte abnormality lasting longer than 72 hours, 
unless the patient has clinical symptoms in which case all grade ≥  3 
abnormalities regardless of duration. Grade ≥  3 amylase or lipase 
elevation not associated with symptoms or clinical manifestation of pancreatitis do not need to be counted. 
 
Patients with an absolute QTc≥ 500msec, QTc< 320msec, or increase of baseline QTc of > 
60msec. 
 
I
f, during the  DLT  observation  period, a patient experiences a toxicity that does not 
clearly fit any of the above DLT  criteria  but in the opi[INVESTIGATOR_180233],  the toxicity may  be considered a DLT  after discussion  with the 
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/[ADDRESS_212067] Center. The person obtaining informed consent will tell the patient that 
1) participation is voluntary, 2) participation or non- participation will not affect their usual care 
and management, and 3) patient confidentiality will be maintained in the event that the results 
of the study are published. The potential toxicities associated with  nilotinib  will be explained 
fully to the patient. Patients will be informed of the need for, blood tests, physical examinations, questionnaires prior to entry into the study and at several specified intervals 
during study period. Patients will be provided with a consent form to review, and all questions 
will be answered.  
 
In th
is phase Ib study, all participants will receive nilotinib  during first cycle  (Schedule A with 
weekly paclitaxel) and during the second cycle (Schedule B with dose dense paclitaxel) .  
 
S
chedule A (weekly paclitaxel): On cycle 1 days 1, 8, 15 paclitaxel infusion will be given at a 
dose of 80mg/m2 as shown in Schema. Duration of paclitaxel is for 12 weekly doses unless 
there is a clinical indication to terminate therapy per treating physician.   
 
• On cycle 1 day 7 and day 14, nilotinib will be taken once a day 24 hours before 
paclitaxel infusion. On day 8 and day 15, nilotinib will be taken once a day 30 minutes 
before paclitaxel infusion.  
 
• Clinic visits and or research visits (see calendar) will take place prior to nilotinib 
administration, 24 hour before paclitaxel infusion to ensure that patients are cleared for 
therapy. When no nilotinib is being administered, patients are seen on day of paclitaxel 
infusion.  
 
Schedule B (dose dense paclitaxel): On cycle 1 day 1 paclitaxel infusion will be given at a dose 
of 175mg/m2 every 2 weeks as shown in Schema. Duration of paclitaxel is for 4 doses unless 
there is a clinical indication to terminate therapy per treating physician.   
 
• On cycle 1 day 14, nilotinib will be taken once a day 24 hours before paclitaxel infusion. On day 1 cycle 2, nilotinib will be taken once a day 30 minutes before paclitaxel 
infusion.  
 
• Clinic visits and or research visits (see calendar) will take place prior to nilotinib 
administration, 24 hour before paclitaxel infusion to ensure that patients are cleared for 
therapy. When no nilotinib is being administered, patients are seen on day of paclitaxel 
infusion.  
 
Self-report diaries (adverse events, record of study drug doses taken/missed) will be collected, 
and pi[INVESTIGATOR_180234]. Medications and supplements will 
be reviewed with participants. A history and physical examination will be performed at 
beginning of each cycle. Study drugs will be dispensed once at the initiation of study protocol with enough pi[INVESTIGATOR_132918] a cycle of treatment. Pi[INVESTIGATOR_180235] #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 21 of 42  each cycle through pi[INVESTIGATOR_180236].  
 If the patient’s chemotherapy is held, the patients should also hold study medication.   
 
7.2 Study Calendar  
 
Baseline evaluations are to be conducted within 2 weeks prior to start of protocol therapy. In the event that the patient’s condition is deteriorating, laboratory evaluations should be repeated within [ADDRESS_212068] +/ - 2 day window, unless otherwise noted.  Off-treatment follow up will occur at 3 
months and at 6 months  after completion of paclitaxel therapy .  Patients removed from study for 
unacceptable adverse event(s) will be followed until resolution or stabilization of the adverse event.  (see study calendar s, below)
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 22 of 42  Study Calendar  Phase Ib  – Schedule A (weekly paclitaxel)  
 Pre 
study  C
1 
D
1 C1 
D7 C1 
D8 C1
D 
14 C1 
D 15 C2 
D1 C2 
D8 C2 
D 15 C3-4 
D1 C3-
4 
D8 C3-4 
D 15   (3 month 
follow up after 
completion of 
paclitaxel) 6 month follow 
up) after 
completion of 
paclitaxel 
Nilotini b   X X X X         
Paclitaxel   X  X  X X X X X X X   
Informed 
consent  X              
Medical 
History  X              
Concurrent 
Meds  X X X  X  X   X   X X 
Physical Exam  X X             
Vital Signs  X X X X X X X X X X X X X X 
Height  X X             
Weight  X X X X X X X X X X X X X X 
Performance 
Status  X X X X X X X   X   X X 
CBC w/ diff, 
plts X X X X X X X X X X X X   
Serum 
chemistry 
magnesium  X X X X X X X   X     
ECG 
(perfomed in 
triplicate)  X X X  X          
Adverse Event 
evaluation by 
[CONTACT_63394]   X X X X X X X X X X X X X 
B-HCG  for 
premenopausa
l women   X             
PK studies*   X X X           
CIPN 20  X X  X  X X   X   X X 
*Please see section 8.1 for detailed PK schedule 
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 23 of 42   
 Study Calendar  Phase Ib  – Schedule B (dose dense paclitaxel)  
 Pre 
study  C1 
D1 C1D 
14 C2D1 C3D1  C4D1   (3 month follow  up 
after completion of 
paclitaxel) 6 month follow up) 
after completion of 
paclitaxel 
Nilotini b   X X     
Paclitaxel   X  X X X   
Informed consent  X        
Medical History  X        
Concurrent Meds  X X X  X  X X 
Physical Exam  X X       
Vital Signs  X X X X X X X X 
Height  X X       
Weight  X X X X X X X X 
Performance Status  X X X X X  X X 
CBC w/ diff, plts  X X X X X X   
Serum chemistry magnesium  X X X X X    
ECG (perfomed in triplicate)  X X X      
Adverse Event evaluation by 
[CONTACT_63394]   X X X X X X X 
B-HCG  for premenopausal 
women   X       
PK studies*(175mg/m2)   X X X     
CIPN 20  X X  X X  X X 
*Please see section 8.1 for detailed PK schedule  
  
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 24 of 42   
7.3  Adverse Events Associated with Nilotinib and Paclitaxel  
 
 
7.3.1 Adverse Events Reported on Niloti nib Trials  
 
• Blood and lymphatic system disorders:  myelosuppression, including grade 3-4 
thrombocytopenia, neutropenia and anemia, serious hemorrhagic events including 
intracranial hemorrhage.  
 
• Cardiac disorders:   QTC prolongation, ischemia, pericardial effusions, hypertension. 
 
• Eye disorders:  N/A 
 
• Gastrointestinal disorders:  pancreatitis and elevated serum lipase, upper abdominal 
pain, nausea, constipation or diarrhea.  
• General disorders and administration site conditions:   fatigue, pyrexia, asthenia, fluid 
retention.  
 
• Hepatobiliary disorders:  AST/ALT elevations, hyperbilirubinemia.  
 
• Investigations:  elevated lipase, hyperglycemia, elevated bilirubin, elevated ast, elevated 
alt, elevated alkaline phosphatase, elevated lipoprotein cholesterol, elevated total cholesterol, elevated blood triglycerides.  
 
• Metabolism and nutrition disorders:  hyperglycemia, electrolyte abnormalities, 
including hypophosphatemia, hypokalemia, hypocalcemia, hyponatremia. Nilotinib capsules contain lactose.  
 
• Musculoskeletal and connective tissue disorders: myalgias, arthralgias, muscle spasm.  
 
• Nervous system disorders: headache.  
 
• Psychiatric disorders:  N/A 
 
• Renal and urinary disorders:   N/A  
 
• Respi[INVESTIGATOR_696], thoracic and mediastinal disorders: pleural effusions.  
 
• Skin and subcutaneous tissue disorders: dry skin, alopecia. 
 
• Vascular disorders:  peripheral arterial occlusive disease (increased frequency at higher 
doses.  
 T
here are no genotoxicity, carcinogenicity, developmental and reproductive studies conducted 
with nilotinib. Women of childbearing potential should not become pregnant or breastfeed and 
men should not father a child during the study. All subjects must use acceptable contraceptive 
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/[ADDRESS_212069] dose of nilotinib, or  if abortion occurs, whether accidental, therapeutic, or spontaneous, it should always 
be classified as serious. Any congenital anomaly/birth defect in a child conceived during the study or within [ADDRESS_212070] dose of nilotinib should be recorded and reported as an SAE.  
 • Female patients should not breastfeed a baby [CONTACT_56035]. • Female patients must NEVER donate ova while or after being treated with nilotinib.  
 All patients are prohibited from donating blood while on study and for [ADDRESS_212071] 
dose of nilotinib. 
 For any grade ≥  2 QTC prolongation or any grade ≥  [ADDRESS_212072] of side effects.  
 
• Hematologic : The most common DLT  is myelosuppression, primarily leukopenia. 
 
• Anaphylaxis and severe hypersensitivity reactions: Patients with a history of severe 
hypersensitivity reactions to products containing Cremophor® EL (e.g., cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with paclitaxel. In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with paclitaxel should be premedicated with corticosteroids (such as dexamethasone), diphenhydramine and H2 antagonists (such as famotidine or ranitidine). Since most of these reactions occur du ring the first [ADDRESS_212073] developed severe hypersensitivity reactions should not be re -
challenged with paclitaxel.  
 
• Cardiac : Cardiovascular events observed with paclitaxel include hypotension and 
bradycardia. Severe conduction abnormalities have been documented in < 1% of patients during Paclitaxel therapy and in some cases requiring pacemaker placement. If patients develop significant conduction abnormalities during paclitaxel infusion, appropriate 
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 26 of 42  therapy should be administered and continuous cardiac monitoring should be performed 
during subsequent therapy with paclitaxel.  
• Neurologic : The frequency and severity of neurologic events are dose -dependent. 
Peripheral neuropathy is rarely severe and may be the cause of paclitaxel discontinuation in 1% of patients. Sensory symptoms usually improve or resolve within several months of completi on of treatment. Serious neurologic events such as grand mal seizures, 
syncope, ataxia and neuroencephalopathy are rare. Although the occurrence of peripheral neuropathy is frequent, the development of severe symptomatology is unusual and require s a dose reduction of 20% or greater for all subsequent courses of paclitaxel.  
 
• Gastrointestinal: The most common GI toxicities, which include nausea, vomiting, 
diarrhea and mucositis, are typi[INVESTIGATOR_180237]. These respond well to supportive care with anti - emetics such as prochlorperazine, anti -diarrheal agents such as 
loperamide  and topi[INVESTIGATOR_180238]. Weekly administration of paclitaxel at 
80 mg/m2 is rarely associated with nausea/vomiting and antiemetic pre -medication is 
generally not needed prior to infusion. If patient experience significant naus ea/vomiting 
during or post -infusion, appropriate antiemetic(s) may be added as prophylaxis prior to 
infusion at the treating physician’s discretion.  
• Injection Site Reaction : Injection site reactions, including reactions secondary to 
extravasation, were usually mild and consisted of erythema, tenderness, skin discoloration, or swelling at the injection site. These reactions have been observed more frequently with the 24 -hour infusion than with the 3- hour infusion. Recurrence of skin 
reactions at a site of previous extravasation following administration of paclitaxel at a different site, i.e., ―recall‖, has been reported rarely. Rare reports of more sever e events 
such as phlebitis, cellulitis, induration, skin exfoliation, necrosis, and fibrosis have been received as part of the continuing surveillance of paclitaxel safety. In some cases the onset of the injection site reaction either occurred during a prolonged infusion or was delayed by a week to ten days. Given the possibility of extravasation, it is advisable to closely monitor the infusion site for possible infiltration during drug administration. If extravasation is discovered or the patient develops localized infusion reaction the 
following cold compression protocol is recommended: 
 
o
 Immediately after medical treatment is completed, apply ice pack to the affected for 15- [ADDRESS_212074] 24 -48 hours by [CONTACT_180266]:  
 Cool wash cloth 
 Instant cool/ice pack  
o The limb should be elevated at all times and exercised at least every 4 -6 hours to 
reduce immobility.  
 
• Other : Although 60% of all patients experience arthralgia and myalgia, there is no 
consistent relationship between the dose or schedule of paclitaxel and the frequency or these events. The symptoms, which usually begin [ADDRESS_212075] all patients receiving paclitaxel experience alopecia. Nail 
changes (changes in pi[INVESTIGATOR_180239]; lifting of the nails) are uncommon with frequency of about 2%. Occasionally, edema is seen at a rate of  about 
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 27 of 42  5%. It is usually of mild severity and gradually reversible following discontinuation of 
paclitaxel.  
 
• Pregnancy : Paclitaxel can cause fetal harm when administered to a pregnant woman. 
Administration of paclitaxel during the period of organogenesis to rabbits at doses of 3.0 mg/kg/day (about 0.2 the daily maximum recommended human dose on a mg/m
2 basis) 
caused embryo and fetotoxicity, as indicated by [CONTACT_161798], increased resorptions, and increased pregnancy loss. There are no adequate and well -controlled 
studies in pregnant women. If paclitaxel is used during pregnancy, or if the pati ent 
becomes  pregnant while receiving this drug, the patient should be apprised of the 
potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.  
• Carcinogenesis, Mutagenesis, Impairment of Fertility : The carcinogenic potential of 
paclitaxel has not been studied. Paclitaxel has been shown to be clastogenic in vitro  
(chromosome aberrations in human lymphocytes) and in vivo  (micronucleus test in mice). 
Paclitaxel was not mutagenic in the Ames test or the CHO/HGPRT gene mutation assay. 
Administration of paclitaxel prior to and during mating produced impairment of fertility 
in male and female rats at doses equal to or greater than 1 mg/kg/day (about 0.04 the daily 
maximum recommended human dose on a mg/m2 basis). At this dose, paclitaxel caused 
reduced fertility and reproductive indices, and increased embryo- and fetotoxicity.   7.3.[ADDRESS_212076] a QTC greater than 480 msec while receiving nilotinb, the following measures are required:  
 
1) Withhold nilotinib, and perform an analysis of serum potassium and magnesium, 
and if below lower limit of normal, correct with supplements to within normal 
limits.   Concomitant medication usage must be reviewed  
2) Resume within 14 days at prior dose if QTc returns to less than 450msec and to 
within 20msec of baseline.  Repeat E CG in triplicate with weekly dosing of 
nilotinib  
3) Discontinue nilotinib and end study participation if QTc remains elevated to 
greater than 480msec after [ADDRESS_212077] a marked baseline prolongation of QT/QTc interval (e.g., repeated 
demonstration of a QTc of > 450msec) or a history of additional risk factors for TdP 
(e.g., heart failure, hypokalemia, family history of Long QT Syndrome) will be excluded 
from study. Patients with an absolute QTc≥ 500msec, QTc< 320msec or increase of 
baseline QTc of > 60msec will discontinue treatment but will still be followed .  
  
 CORRELATIVE STUDIES  
 The focus of this trial will be an assessment of safety, tolerability and determination of a 
recommended future phase II dose of the study regimen. The future phase II component of the 
trial will ascertain the efficacy of nilotinib vs placebo in preventing paclitaxel- related 
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 28 of 42  neuropathy. C orrelatives for the trial are as follows:  
 
The effect of nilotinib on pharmacokinetics (PK) of paclitaxel and the effect of paclitaxel on PK 
of nilotinib will be evaluated to ensure  that these agents do not have clinically significant 
interactions.  We will evaluate real time PK data to ensure that there is no adverse negative effect on paclitaxel PKs. We will assess all patient data for the first 6 patients before proceeding, to ensure that all PKs are within expected level of no interaction between the two drugs.   
 
8.1 Integrated Correlative Studies: PK of Nilotinib and Paclitaxel 
 The effect of nilotinib on the PK of paclitaxel, as well as the effect of paclitaxel on the PK of nilotinib will be studied.   Based on our recent preclinical experience of nilotinib given in combination with paclitaxel, we anticipate that nilotinib will not affect the disposition profile of paclitaxel and vice versa. The expectation that nilotinib is unlikely to influence the pha rmacokinetics of paclitaxel would be 
consistent with previously reported studies confirming that other OATP1B1- inhibiting TKIs 
identified from our screens, such as axitinib, and sorafenib, do not alter the systemic exposure to paclitaxel. The noted NCI study confirmed our preclinical anticipation, there were no observed adverse PK interactions between nilotinib and paclitaxel. Although the drug- drug interaction in a 
clinical setting is highly unlikely, we will perform real- time PK analyses for both paclitax el, 
nilotinib and in combination for parent and metabolites.  The PK assessments of nilotinib and paclitaxel are summarized below.  
 8.1.1 Schedule for collection of specimen(s): 
 During the Phase  Ib trial, PK will be obtained at baseline (within 15 min of pre -dose), during drug 
administration (within 5 min of the end of infusion), and at [ADDRESS_212078] -dose for a total of 7 blood samplings . The PK of both 
paclitaxel and nilotinib will be assessed prior to administration of nilotinib, prior to administration of paclitaxel, during the administratio n of paclitaxel, and at 3 defined time -points ranging up to 
2.5 hours after paclitaxel  administration, for up to 7 blood samplings for combination treatment.  
 For Schedule A: weekly dose of 80mg/m
2 paclitaxel  
• The PK of paclitaxel will be measured on Day 1 (paclitaxel given as a single agent) at the 
following times:  
 
• Pre -dose (within 15 min) 
• Immediately prior to end of infusion of paclitaxel (within 5 min)  
• 0.5 hour after end of infusion (±5 min) 
• 1.5 hour after end of infusion (±5 min) • 2.5 hours after end of infusion (±5 min)  
• 4.5 hours after end of infusion (±5 min)  
 
• The PK of nilotinib will be measured during Day 7. N ilotinib is given as a single agent, 24 
hours prior to paclitaxel infusion at following times:  
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 29 of 42   
• Pre -dose (within 15 min) 
• 0.5 hour after taking the pi[INVESTIGATOR_4382] (±5 min) 
• 1.5 hour after taking the pi[INVESTIGATOR_4382] (±5 min) • 2 hours after taking the pi[INVESTIGATOR_4382] (±5 min) • 3 hours after taking the pi[INVESTIGATOR_4382] (±5 min) • 4 hours after taking the pi[INVESTIGATOR_4382] (±10 min) • 6 hour after taking the pi[INVESTIGATOR_4382] (±10 min) 
 
• The PK of nilotinib and paclitaxel will be measured on Day 8. N ilotinib given 30 min before 
paclitaxel infusion at the following times:  
 
• Pre -dose of nilotinib (within 15 min) 
• Prior to starting paclitaxel infusion (within 5 min) 
• Immediately prior to end of infusion of paclitaxel (within 5 min)  
• 0.5 hour after end of paclitaxel infusion (±5 min) • 1.5 hours after end of paclitaxel infusion (±5 min) • 2.5 hours after end of paclitaxel infusion (±5 min) • 4 hours after end of paclitaxel infusion (±10 min) 
 For Schedule B: Every two weeks dose dense of 175mg/m
2 paclitaxel  
• The PK of paclitaxel will be measured on Day 1 (paclitaxel given as a single agent) at the following times:  
 
• Pre -dose (within 15 min) 
• 1.5 hour after infusion of paclitaxel (within 5 min)  • Immediately prior to end of infusion of paclitaxel (within 5 min)  
• 0.5 hour after end of infusion (±5 min) • 1.5 hour after end of infusion (±5 min) • 2.5 hours after end of infusion (±5 min)  
 
• The PK of nilotinib will be measured during Day 14, nilotinib is given as a single agent, 24 
hr prior to paclitaxel infusion at following times:  
• Pre -dose (within 15 min) 
• 0.5 hour after taking the pi[INVESTIGATOR_4382] (±5 min) • 1.5 hour after taking the pi[INVESTIGATOR_4382] (±5 min) • 2 hours after taking the pi[INVESTIGATOR_4382] (±5 min) • 3 hours after taking the pi[INVESTIGATOR_4382] (±5 min) • 4 hours after taking the pi[INVESTIGATOR_4382] (±10 min) • 6 hour after taking the pi[INVESTIGATOR_4382] (±10 min) 
 
• The PK of nilotinib and paclitaxel will be measured on Cycle 2 Day 1, nilotinib is given 30 
min before paclitaxel infusion at the following times:  
 
• Pre -dose of nilotinib (within 15 min) 
• Prior to starting paclitaxel infusion (within 5 min) 
• 1.5 hour after infusion of paclitaxel (within 5 min)  
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 30 of 42  • Immediately prior to end of infusion of paclitaxel (within 5 min)  
• 0.5 hour after end of paclitaxel infusion (±5 min) 
• 1.5 hours after end of paclitaxel infusion (±5 min) • 2.5 hours after end of paclitaxel infusion (±5 min) 
 
8.1.2 Procedure for collection of specimen(s):  
 Samples should be collected via a peripheral blood draw in the contralateral arm to the infusion. In the event when a patient has poor venous access and has an existing and functional central venous catheter, sampling through the central line is acceptable. Patients without venous access will be allowed to have a port placed prior to initiation of study therapy per discretion of the treating physician. Patients without a port will have an option of having a central line inserted during treatment visits, esp ecially on days that require timed blood draws. Each sample will be 
collected into a 6- mL lithium heparin (green top) vacutainer tube. Immediately after collection, 
the tube is inverted [ADDRESS_212079] tube on ice until centrif ugation. 
The PK specimen will then be centrifuged at 1,200 xg for 10 min at 4°C within 1 hour of sample collection. The plasma layer will be transferred into three (3) 2 -mL cryovials in roughly equal 
proportions and frozen immediately at ( -70) 
oC.  An accompan ied PK requisition form must be 
completed for each course of PK sampling. A copy of the completed form must be included with the shipme nt of the samples for analysis.  
 
8.1.3 Procedure for analysis of specimen(s):  
 We anticipate that OATP1B1 function can be modulated by [CONTACT_180267]. This would be consistent with our prior work indicating that the plasma concentration- time profiles of paclitaxel are  inversely related to 
corresponding drug levels in liver, and that the presence of Kolliphor EL in the clinical paclitaxel formulation is the main determinant of drug disposition properties, and that this excipi[INVESTIGATOR_180240]1B -type transporte rs on paclitaxel levels in plasma. This hypothesis will be 
prospectively tested in all patients enrolled on the Phase 1b study by [CONTACT_180268]. Plasma samples will be analyzed  in real time  for paclitaxel and its main liver metabolites by [CONTACT_29864]/MS/MS  in the laboratory 
of Dr .  Shuiying Hu in the College of Pharmacy. In addition, we anticipate that paclitaxel will not 
alter the absorption and distribution profiles of nilotinib, cons idering that the principal elimination 
pathway of nilotinib, CYP3A4- mediated metabolism, is insensitive to inhibition by [CONTACT_114461]. To 
confirm this hypothesis, plasma samples will be also analyzed for nilotinib by [CONTACT_180269]/MS/MS. All pharmacokinetic parameters will be calculated using standard non -compartmental methods . 
 8.1.4 Procedure for banking of specimen(s):  
 After samples are analyzed, any unused, leftover samples will be retained to allow for other 
biomarker analysis in the future as the pre -clinical research progresses.  Samples will be stored 
indefinitely in -[ADDRESS_212080] on leftover samples.  
 
8.2 Integrated Correlative Studies: Biomarkers of OATP1B1  
 In order to assess the degree of OATP1B1 inhibition by [CONTACT_180258], analysis of 
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 31 of 42  glycochenodeoxycholate sulfate (GCDGA -S) and chenodeoxycholate -24-glucuronide (CDCA -
24G) levels will be performed as validated surrogate endogenous substrates of OATP1B. Previous 
clinical studies have indicated that the AUC of GCDCA- S can be increased >[ADDRESS_212081] nilotinib dose will be collected and subjected to 
LC/MS/MS in a negative multiple reaction monitoring mode to quantify concentrations of the test compounds. Concentrations of total and unbound nilotinib will also be determined in the same 
samples by [CONTACT_180270]/MS/MS and micro -equilibrium dialysis, respectively. 
This information will be utilized to confirm that plasma levels of nilotinib associated with the applied test doses are in the anticipated ranges and are consistent with the inhibition constant of nilotinib for OATP1B1 derived from cell cu lture studies.  
 
 ADVERSE EVENT REPORTING  
 Adverse event: Any unfavorable and unintended sign (including abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure; also an 
“unanticipated problem” of any nature (e.g., psychological or social harm) (designated as unrelated, definitely related, probably related, or possibly related; see below)  Serious adverse event : A
 ny adverse event that is fatal or life threatening, is permanently disabling, 
requires inpatient hospi[INVESTIGATOR_34908], or results in a congenital anomaly or birth defect.  Life-t
hreatening event : Any adverse event in which the subject is at immediate risk of death from 
the reaction as it occurs; does not include a reaction that, if it were to occur in a more serious form, might cause death  
 Unexpected event :
  Any adverse event that is not identified in nature, severity, or frequency in the 
investigator brochure, study protocol, consent form, or IND application; or the event was more serious than anticipated.     
9.1 
Attribution of the A dverse Events 
 
Definite :   AE is CLEARLY RELATED to the study treatment.   
Probable : AE is LIKELY RELATED  to the study treatment.  
Possible : AE MAY BE RELATED to the study treatment.  
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 32 of 42  Unlikely : AE is DOUBTFULLY RELATED to the study treatment. 
Unrelated : AE is CLEARLY NOT  related to the study treatment  
 
9.[ADDRESS_212082] 
access to a copy of the CTCAE version 5.0. A copy of the CTCAE version 5.0 can be downloaded from the CTEP web site  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . 
 For expedited reporting purposes only:  
• AEs for the agent that are bold and italicized in the CAEPR (i.e., those listed in the SPEER column, Section 7.1.1) should be reported through CTEP -AERS only if the 
grade is above the grade provided in the SPEER. 
 All adverse events must be documented in detail within the medical record. The patient will be observed and monitored carefully until the condition resolves, stabilizes, or its cause is identified. All adverse events, including laboratory abnormalities, will be followed up according to good medical practices. Information to be recorded includes the following:  
 
1. Specific type of reaction.  
2. Duration of reaction.  
3. Severity/grade of reaction according to the NCI Common Terminology Criteria for  
Adverse Events v5.0 (CTCAE).  
4. Suspected cause of the reaction (i.e. possibly or probably related to one of the following: study intervention, progression of disease, concurrent medications, concurrent illness, or other factors).  
5. Patient’s response to medical interventions.  
 
9.[ADDRESS_212083] chemotherapy are not attributable to study intervention (gait and balance assessment) and therefore not subject to reporting. However, they will be collected in order to evaluate associations with gait and balance deficits. S ince it is difficult to discern which 
AEs may impact gait and balance testing, all AEs will be collected, not just neuropathy symptoms. Although unlikely, some unrelated symptoms may impact gait and balance and may also be indirectly related to neuropathy symptoms (e.g. cytopenias and fatigue may impact balance and gait).   
  DATA REPORTING / REGULATORY REQUIREMENTS  
 
10.[ADDRESS_212084]  
 
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/[ADDRESS_212085] of The Ohio State University prior to implementation.  
 
10.3 Informed Consent  
 All potential candidates for the study will be given a copy to read of the consent form for the study. The Principal Investigator [INVESTIGATOR_1238]/or designee will explain all aspects of the study in lay language and answer all the candidate’s questions regarding the study. If the candidate desires to participate in the study, she will be asked to sign the Informed Consent. The study agent will not be released to a subject without a signed Informed Consent. Elements of informed consent include explanations of 1) the pur pose of the trial, 2) what the study entails, 3) alternate treatments, 4) 
expenses and inconveniences to be incurred, 5) discomfort and risks to the subject, 6) whether she will receive payment for participation in the study, 7) contact [CONTACT_180271], 8) subject rights as a result of illness or injury from trial participation, 9) subjects right to withdraw from the trial at any time without prejudice, 10) confidentiality of trial participation.  
 
10.[ADDRESS_212086]. Nicole Williams’  office and/or research 
laboratories.  
 
10.[ADDRESS_212087] and reported immediately to the PI. Deviations that meet the criteria for Immediate Event Reporting 
(http://orrp.osu.edu/irb/event/index.cfm ) such as those that increase risks to subjects and/or 
compromise scientific integrity will be reported immediately to the IRB.  
 
10.[ADDRESS_212088] continuous review of data and patient safety at their regular Disease Group meetings (at least monthly) and t he discussion will be documented in 
the minutes. The PI [INVESTIGATOR_180241]/benefit ratio of the trial changes. Frequency and severity of  adverse events will be reviewed by [CONTACT_978] [INVESTIGATOR_180242] #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 34 of 42  known about the agent/device from other sources; including published literature, scientific 
meetings and discussions with the sponsors, to determine if the trial should be terminated before completion. Serious adverse events and responses will also be revi ewed by [CONTACT_180272] (DSMC). The PI [INVESTIGATOR_37354] a progress report biannually that will be reviewed by [CONTACT_37394]. All reportable Serious Adverse Events (SAE) will also be reported to the IRB of record as per the policies of the IRB.  
 
10.[ADDRESS_212089] (EPIC).  
 
10.[ADDRESS_212090] to the patient. Pi[INVESTIGATOR_180243], with the start date and number of pi[INVESTIGATOR_180244]. The drugs will be provided in 
sufficient supply for one cycle of taxane chemotherapy . Pi[INVESTIGATOR_180245]’s follow -up visits, and any unused capsules will be documented and counted to ensure 
proper adherence. The pi[INVESTIGATOR_180246]. Additionally, there will be no charge for research -related blood work. 
Imaging is considered as part of standard of care testing.  
 
10.[ADDRESS_212091]. The patient will be observed and monitored carefully until the condition resolves, stabilizes, or its cause is identified. All adverse events, including laboratory abnormalities, will be followed up according to good 
medical practices. Information to be recorded includes the following:  
1. Specific type of reaction.   
2. Duration of reaction.  
3. Severity/grade of reaction according to the NCI Common Terminology Criteria for  
4. Adverse Events 5.0 (CTCAE).  
5. Suspected  cause of the reaction (i.e. possibly or probably related to one of the following: 
study treatment, progression of disease, concurrent medications, concurrent illness, or other factors).   
6. Changes made in the administration of the study drugs and other actions taken to alleviate the clinical event.   
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 35 of 42  7. Patient’s response to medical interventions.  
 
10.13 Reporting  
 
According to FDA regulations (21 CFR 312.32), IND safety reports shall address “any adverse experience associated with the use of a drug that is both serious and unexpected.” The IRB will be notified of any adverse event that occurs on the study regardless of severity . 
  Federal policy [45 CFR 46.116(b)(5)] also requires that investigators inform subjects of any important new information that might affect their willingness to continue participating in the research. When an adverse event necessitates changes to the consent/ assent form(s) and/or 
protocol, or that notification is given to currently or previously enrolled subjects, an amendment request will be submitted in conjunction with the adverse event report. The IRB will make a determination whether any new findings, new  knowledge, or adverse effects should be 
communicated to subjects.  
 In accordance with IRB guidelines, serious adverse events will be reported within 10 days of the investigator’s or research staff members’ learning of the event to The Ohio State University Institutional Review Board. OSU IRB Event Reports should be submitted through BuckIRB at: http:/orrp.osu.edu/irb/buck- IRB/. Events resulting in temporary or permanent interruption of 
study activities by [CONTACT_180273] 48 hours whenever possible.  In addition, all adverse events regardless of severity 
will be reported in the same manner within 10 calendar days of the investigator’s or research staff members’ learning of the event.  
 All events that may represent unanticipated problems involving risks to subjects or  others will be 
promptly reported (as described above), regardless of whether they occur during or after the study, 
or involve a subject who has withdrawn from or completed study participation. If changes to the research or consent process are proposed as a result of the event  or if additional information will 
be provided to current and/or past participants, an amendment request will also be submitted for IRB review.  In addit ion, all adverse events regardless of grade will be reported as per the FDA 
reporting requirements below (21 CFR Part 312) including Grade 1 and Grade 2 events, which will be reported within 10 calendar days whether participants were hospi[INVESTIGATOR_180247].  
 
Related events involving risk but not meeting the prompt reporting requirements will also be 
reported to the IRB in summary form at the time of continuing review.  
 
Phase I Studies: Expedited Reporting Requirements for Adverse Events that Occur on 
Studies under an IND/IDE within [ADDRESS_212092] Administration of the Investigational Agent/Intervention  
 
FDA REPORTING REQUIREMENTS FOR SERIOUS ADVERSE EVENTS (21 CFR Part 312)  
NOTE: Investigators  MUST  immediately report to the sponsor (NCI) ANY Serious Adverse Events, 
whether or not they are considered related to the investigational agent(s)/intervention (21 CFR 312.64) An adverse event is considered serious if it results in  
 ANY of the following outcomes:  
             1) Death  
             2) A life-threatening adverse event  
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 36 of 42               3) An adverse event that results in inpatient hospi[INVESTIGATOR_9959] ≥ 24  
hours 
             4) A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions  
              ) A congenital anomaly/birth defect. 
             6) Important Medical Events (IME) that may not result in death, be life threatening, or require hospi[INVESTIGATOR_708], based upon medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to  prevent one of the outcomes listed 
in this definition. (FDA, 21 CFR 312.32; ICH E2A and ICH E6).  
ALL SERIOUS  adverse events that meet the above criteria MUST be immediately reported to the NCI 
via electronic submission within the timeframes detailed in the table below.  
Hospi[INVESTIGATOR_15164] 1 and Grade 2 Timeframe  Grade 3 -5 Timeframes  
Resulting in 
Hospi[INVESTIGATOR_059] ≥ 24 hrs  
 
Not resulting in  
Hospi[INVESTIGATOR_059] ≥ 24 hrs  10 Calendar Days  
  
Not required  
 
24 hour 5 calendar days 
NOTE:  Protocol specific exceptions to expedited reporting of serious adverse events are found in the 
Specific Protocol Exceptions to Expedited Reporting (SPEER) portion of the CAEPR. 
Expedited AE reporting timelines are defined as: 
     o “24- Hour; 5 Calendar Days” - The AE must initially be submitted electronically within 24 hours of 
learning of the AE, followed by a complete expedited report within 5 calendar days of the initial 24-hour report.  
     o “10 Calendar Days” - A complete expedited report on the AE must be submitted electronically 
within [ADDRESS_212093] administration of investigational 
agent/intervention and have an attribution of possible, probable, or definite require reporting as follows: Expedited 24 -hour notification followed by [CONTACT_432] 5 calendar days for : 
• All Grade 3, 4, and Grade 5 AEs Expedited 10 calendar day reports for : 
• Grade 2 AEs resulting in hospi[INVESTIGATOR_180248]: May 5, 2011  
 
 
 STATISTICAL CONSIDERATIONS  
 
11.1 Study endpoints  
 
Definition of Primary Endpoint  
• Safety, tolerability and RP2D of nilotinib in combination with paclitaxel.  
 
Definition of Secondary Endpoints  
• PK endpoints such as AUC , CL, Vd, and t1/2 for nilotinib and paclitaxel. 
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 37 of 42  • Quality of life using CIPN -20 questionnaire, d isease- free survival (DFS), event 
free survival (EFS) and overall survival (OS) of nilotinib in combination with 
paclitaxel .  
 
 
11.[ADDRESS_212094] cancer without affecting the plasma pharmacokinetics of paclitaxel. The proposed study design is derived from an adaptive Bayesian method for dose -finding based on trade -offs between the 
probabilities of treatment efficacy and toxicity (EffTox). In this design, treatment efficacy is defined as statistically significant inh ibition of OATP1B1 activity by [CONTACT_180258], without causing 
changes in the pharmacokinetic profiles of paclitaxel. Tolerability of the combination regimen will be evaluated within the first 4 weeks of treatment  (cycles 1 & 2). Doses are selected for 
successive patient cohorts based on a set of efficacy -toxicity trade -off contours that partition the 
two-dimensional outcome probability domain. Priors are established by [CONTACT_180274] -
parameters that optimize the fit of the model to elicited mean outcome probabilities. Published studies have demonstrated that, under a wide range of dose -outcome scenarios, the EffTox method 
has high probabilities of making correct decisions as compared to classic dose -escalation studies 
such as the ‘3+3 Design’ in which the assessment is mainly based on establishing the dose levels associated with dose- limiting toxicity (DLT). Moreover, the EffTox method allows treatment of 
most patients at doses with desirable efficacy -toxicity trade -offs. In the proposed Phase 1b study, 
the maximum sample size will be 20 with cohort size of 2. A total of 4 nilotinib dose levels will be considered, including 50 mg (dose level - 1), 100 mg (dose level 1), 200 mg (dose level 2), and 
300 mg (dose level 3), with the goal to find an optimal dose.   During the proposed EffTox Phase 1b study, both efficacy and toxicity  will be monitored and 
these data used to iteratively inform the dynamic, adaptive model to make dose escalation or de -
escalation decisions. Efficacy in this setting will be OATP1B1 inhibition as defined by a ≥5- fold 
increase in the AUC of GCDCA- S from pre - to post -treatment and/or detectable CDCA -24G 
levels post -treatment; although preliminary data in other populations suggest a potentially much 
larger effect, a 5 -fold increase would be s ufficiently large to indicate effective inhibition.  
 We specified prior distributions and threshold probabilities of efficacy and toxicity for this model; the maximum allowable probability of toxicity will be 0. 33, the minimum probability of efficacy 
will be 0.90, and cut -offs of 0.[ADDRESS_212095] cohort of patients will be enrolled at dose level 1 (nilotinib 100 mg). After each cohort is treated and evaluated for toxicity and efficacy as 
defined in the  context of this trial, these data will inform our dynamic, adaptive model to 
determine dose escalation decisions based on changes to estimated probabilities for toxicity and for efficacy given the data observed. Then next cohort of patients will be treated on the dose level determined from the Bayesian adaptive model. This iterative process is repeated until the maximum sample size or pre -defined stoppi[INVESTIGATOR_180249].  For this phase 1b study, our 
primary objective is to select an optimal, safe nilotinib dose that can temporarily inhibit the function of OATP1B1 in patients with breast cancer without affecting the plasma pharmacokinetics of paclitaxel. We are interested in both toxicity (DLT) and efficacy (OATP1B1 inhibition). The traditional 3+3 design can determine the MTD only accounting for the associated 
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 38 of 42  DLTs at each dose level, but could not determine the optimal dose level using both toxicity and 
efficacy. Therefore, an adaptive Bayesian method for dose -finding based on trade -offs between 
the probabilities of treatment efficacy and toxicity (EffTox) will be used.  After all evaluable patients have been treated , the recommended dose for  the phase II will be the 
highest dose level that satisfies  those two EffTox dose acceptability rules  (dose has acceptable 
toxicity if Prob [prob (Toxicity) < 0.33|data] ≥ 0.1;  dose has acceptable efficacy if 
Prob[proc(Efficacy) < .90|data)≥0.1). A feature of this study design is that we are not bound to 
start our dosing at the lowest dose but rather an expected effective dose; thus, the first cohort will be treated at dose level 1 (100 mg). Assessment of OATP1B1 inhibition and paclita xel plasma 
levels will be performed within one week of sample collection to avoid delays in enrollment of patients on subsequent dose levels. These models will identify admissible sets of doses, where a modification will be that no untested doses will be skipped during dose escalation. The prior hyper- parameters will be computed based on the assumed prior means Prob(Toxicity | dose) = 
{0.02, 0.04, 0.06, 0.08}, and Prob(Efficacy | dose) = {0.2, 0.4, 0.6, 0.8}, for each of the [ADDRESS_212096] ively, with the overall prior effective sample size (ESS) of 1. Simulations are 
carried out using EffTox version 5.0.0, wit h 2000 replications per scenario, and the operating 
characteri stics of this design are summarized in Table 4 If it is highly likely (ie, probabilities 
>0.90) that more than one dose is associated with acceptable rates of efficacy and toxicity, the next cohort of patients will be treated at the dose associated with the stronger degree of OATP1B1 inhibition. The trial will be conducted using EffTox Software (version 5.0.0) developed by [CONTACT_180275]. Adverse events will be classified and attributed using NCI -CTCAE v5.0 and will be 
summarized within and across dose levels.  
 Table 4: Operating characteristics of the EffTox  study design planned, where P
T is the probability 
of toxicity and P E is the probability of efficacy  
 
 
11.3 Statistical Data Analysis  Scenario  Model 
characteristics  Nilotinib dose level  
-1 (50 mg)  1 (100 mg)  2 (200 mg)  3 (300 mg)  None  
1 True P T, PE 0.02, 0.20  0.04, 0.40  0.06, 0.80  0.08, 1.00  -- 
Utility (trade -off) -3.02 -2.04 -0.10 0.73 -- 
% selected  0 0 7 93 0 
# patients treated  0.0 2.0 3.3 14.6 -- 
2 True P T, PE 0.05, 0.10  0.10, 0.50  0.15, 0.85  0.33, 0.95  -- 
Utility (trade -off) -3.55 -1.64 -0.07 -0.22 -- 
% selected  0 0 45 48 7 
# patients treated  0.0 2.1 8.1 9.0 -- 
3 True P T, PE 0.01, 0.50  0.10, 0.70  0.20, 0.90  0.50, 1.00  -- 
Utility (trade -off) -1.51 -0.66 0.00 -0.67 -- 
% selected  0 4 83 8 6 
# patients treated  0.0 2.9 12.8 3.7 -- 
4 True P T, PE 0.01, 0.70  0.20, 0.80 0.30, 1.00  0.60, 1.00  -- 
Utility (trade -off) -0.51 -0.43 0.00 1.00 -- 
% selected  0 30 62 0 8 
# patients treated  0.1 6.2 11.7 1.1 -- 
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 39 of 42   
Adverse events (AEs) will be classified and attributed using NCI CTCAE v5.[ADDRESS_212097] one dose of the therapeutic agents will be evaluable for toxicity and tolerability.  
 Overall  response rate (partial response + complete response) will be summarized  and 95% exact 
binomial confidence interval will be provided.  Progression Free Survival (PFS) will be defined 
as the time from initiation of therapy to the time of RECIST progression or death.  Overall Survival ( OS) will be defined as time from initiation of therapy to death.  Event free survival  
(EFS)  will be defined as time from initiation to breast cancer disease progression . Survival will 
initially be modeled using Kaplan- Meier methods, resulting in median survival times with 95% 
CI.  Survival will be further modeled using Cox proportional hazards models resulting in HRs 
with 95% CI, allowing for adjustment for critical covariates such as age, gender , race/ethnicity .    
 We will explore PK endpoints such as AUC,  CL, Vd, and t1/[ADDRESS_212098] of parameters, based on well- established 
PK profile for both paclitaxel and nilotinib . We will use graphical analyses as well as repeated 
measure models (linear or nonlinear mixed models, generalized estimating equations [GEE]) to assess the PK and PD markers described above in relatio n to clinical treatment outcomes, 
recognizing some inherent limitations due to sample size.  
   
 REFERENCES  
 1. Tinetti ME. Clinical practice. Preventing falls in elderly persons. N Engl J Med. 2003;348(1):42-9. Epub 2003/01/03. doi: 10.1056/NEJMcp020719. PubMed PMID: 12510042. 2. Balducci S, Iacobellis G, Parisi L, Di Biase N, Calandriello E, Leonetti F, Fallucca F. 
Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diabetes Complications. 2006;20(4):216-23. Epub 2006/06/27. doi: 10.1016/j.jdiacomp.2005.07.005. PubMed PMID: 16798472. 3. Bakitas MA. Background noise: the experience of chemotherapy -induced peripheral 
neuropathy. Nurs Res. 2007;56(5):323-31. Epub 2007/09/12. doi: 10.1097/01.NNR.[PHONE_3860].[ZIP_CODE].79. PubMed PMID: 17846553. 4. Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, Le-Lindqwister NA, Soori GS, Jaslowski AJ, Novotny PJ, Lachance DH. Natural history of paclitaxel -associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin 
Onco l. 2011;29(11):1472-8. Epub 2011/03/09. doi: 10.1200/JCO.2010.33.0308. PubMed PMID: 
21383290; PMCID: PMC3082985. 5. Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, 
Fadul CE, Knox C, Le- Lindqwister N, Gilman PB, Shapi[INVESTIGATOR_24126], Alliance for Clinical Trials in 
O. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy -
induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359-
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 40 of 42  67. Epub 2013/04/04. doi: 10.1001/jama.2013.2813. PubMed PMID: 23549581; PMCID: 
PMC3912515. 6. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner -Johnston N, Bak K, Loprinzi CL, American Society of Clinical O. 
Preven tion and management of chemotherapy-induced peripheral neuropathy in survivors of 
adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941-67. doi: 10.1200/JCO.2013.54.0914. PubMed PMID: 24733808. 7. Leblanc AF, Sprowl JA, Alberti P, Chiorazzi A, Arnold WD, Gibson AA, Hong KW, Pi[INVESTIGATOR_180250], Chen M, Huang KM, Chodisetty V, Costa O, Florea T, De Bruijn P, Mathijssen RH, Reinbolt RE, Lustberg MB, Sucheston-Campbell LE, Cavaletti G, Sparreboom A, Hu S. OATP1B2 -deficiency protects against paclitaxel -induced neurotoxicity. J Clin Invest. 
2018;128(2):[Epub ahead of print]. 8. Xia B, Heimbach T, He H, Lin TH. Nilotinib preclinical pharmacokinetics and practical 
application toward clinical projections of oral absorption and systemic availability. Biopharmaceutics & drug disposition. 2012;33(9):536-49. Epub 2012/10/26. doi: 10.1002/bdd.1821. PubMed PMID: 23097199. 
9. Takehara I, Terashima H, Nakayama T, Yoshikado T, Yoshida M, Furihata K, Watanabe 
N, Maeda K, Ando O, Sugiyama Y, Kusuhara H. Investigation of Glycochenodeoxycholate 
Sulfate and Chenodeoxycholate Glucuronide as Surrogate Endogenous Probes for Drug Inter action Studies of OATP1B1 and OATP1B3 in Healthy Japanese Volunteers. Pharm Res. 
2017;34(8):1601-14. Epub 2017/05/28. doi: 10.1007/s11095-017-2184-5. PubMed PMID: 28550384. 10.  Galetin A, Brouwer KLR, Tweedie D, Yoshida K, Sjostedt N, Aleksunes L, Chu X, Evers R, Hafey MJ, Lai Y, Matsson P, Riselli A, Shen H, Sparreboom A, Varma MVS, Yang J, Yang X, Yee SW, Zamek-Gliszczynski MJ, Zhang L, Giacomini KM. Membrane transporters in drug development and as determinants of precision medicine. Nat Rev Drug Discov. 2024;23(4):255-80. Epub 20240124. doi: 10.1038/s41573- 023-[ZIP_CODE]- 1. PubMed PMID: 
38267543; PMCID: PMC11464068. 11. Kikuchi R, Chothe PP, Chu X, Huth F, Ishida K, Ishiguro N, Jiang R, Shen H, Stahl SH, Varma MVS, Willemin ME, Morse BL. Utilization of OATP1B Biomarker Coproporphyrin -I to 
Guide Drug- Drug Interaction Risk Assessment: Evaluation by [CONTACT_180276]. Clin 
Pharmacol Ther. 2023;114(6):1170 -83. Epub 20231011. doi: 10.1002/cpt.3062. PubMed PMID: 
37750401. 12. Yoshida K, Jaochico A, Mao J, Sangaraju D. Glycochenodeoxycholate and glycodeoxycholate 3-O- glucuronides, but not hexadecanedioate and tetradecanedioate, detected 
weak inhibition of OATP1B caused by [CONTACT_180277]-0810 in humans. Br J Clin Pharmacol. 2023;89(6):1903-7. Epub 20230214. doi: 10.1111/bcp.[ZIP_CODE]. PubMed PMID: 36735594. 13. Li Y, Drabison T, Nepal M, Ho RH, Leblanc AF, Gibson AA, Jin Y, Yang W, Huang KM, Uddin ME, Chen M, DiGiacomo DF, Chen X, Razzaq S, Tonniges JR, McTigue DM, Mims AS, Lustberg MB, Wang Y, Hummon AB, Evans WE, Baker SD, Cavaletti G, Sparreboom A, Hu S. T argeting a xenobiotic transporter to ameliorate vincristine -induced 
sensory neuropathy. JCI Insight. 2023;8(14). Epub 20230724. doi: 10.1172/jci.insight.164646. PubMed PMID: 37347545; PMCID: PMC10443802. 14. Holbeck SL, Camalier R, Crowell JA, Govindharajulu JP, Hollingshead MG, Anderson LW, Polley EC, Rubinstein L, Srivastava AK, Wilsker DF, Collins JM, Doroshow JH. The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detectio n 
of Anticancer Drug Pairs with Enhanced Therapeutic Activity. Cancer research. 2017. doi: 
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 41 of 42  10.1158/0008-5472.CAN-17-0489. PubMed PMID: 28446463. 
15. Hidalgo M, Amant F, Biankin AV, Budinska E, By[CONTACT_180278], Caldas C, Clarke RB, de Jong S, Jonkers J, Maelandsmo GM, Roman-Roman S, Seoane J, Trusolino L, Villanueva A. Patient -derived xenograft models: an emerging platform for translational cancer research . 
Cancer discovery. 2014;4(9):998-1013. doi: 10.1158/2159-8290.CD-14-0001. PubMed PMID: 25185190; PMCID: 4167608. 16. Wolf SL, Barton DL, Qin R, Wos EJ, Sloan JA, Liu H, Aaronson NK, Satele DV, Mattar BI, Green NB, Loprinzi CL. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy -induced peripheral neuropathy (CIPN) as measured by [CONTACT_120372]-CIPN20 instrument, N06CA. Support Care Cancer. 2012;20(3):625-32. Epub 2011/04/12. doi: 10.1007/s00520-011-1141-9. PubMed PMID: 21479990; PMCID: PMC3329939. 17. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, Hoang -
Xuan K, Lanteri-Minet M, Grant R, Huddart R, Moynihan C, Maher J, Lucey R. The development of an EORTC quality of life questionnaire to assess chemotherapy -induced 
peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer. 2005;41(8):1135-9. Epub 2005/05/25. doi: 10.1016/j.ejca.2005.02.012. PubMed PMID: 15911236. 
18. Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao TJ, Lepore J, Gilewski T, 
Currie V, Crown J, et al. Phase II trial of paclitaxel by [ADDRESS_212099] cancer. J Clin Oncol. 1995;13(10):2575-81. Epub 1995/10/01. doi: 10.1200/JCO.1995.13.10.2575. PubMed PMID: 7595709. 19. Hudis CA, Seidman AD, Crown JP, Balmaceda C, Freilich R, Gilewski TA, Hakes TB, Currie V, Lebwohl DE, Baselga J, Raptis G, Gollub M, Robles M, Bruno R, Norton L. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breas t cancer. J 
Clin Oncol. 1996;14(1):58-65. Epub 1996/01/01. doi: 10.1200/JCO.1996.14.1.58. PubMed PMID: 8558221. 20. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil -based paclitaxel in women with breast cancer. J Clin Oncol. 
2005;23(31):7794-803. Epub 2005/09/21. doi: 10.1200/JCO.2005.04.937. PubMed PMID: 16172456. 21. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971;93(9):2325-7. Epub 1971/05/05. PubMed PMID: 5553076. 22. Horwitz SB. Personal recollections on the early development of taxol. J Nat Prod. 
2004;67(2):136-8. Epub 2004/02/28. doi: 10.1021/np0304464. PubMed PMID: 14987047. 23. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by [CONTACT_180279]. Nature. 1979;277(5698):665-7. Epub 1979/02/22. PubMed PMID: 423966. 24. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med. 1995;332(15):1004-14. Epub 1995/04/13. doi: 10.1056/NEJM199504133321507. PubMed PMID: 7885406. 25. Berger MJ, Vargo C, Vincent M, Shaver K, Phillips G, Layman R, Macrae E, Mrozek E, 
Ramaswamy B, Wesolowski R, Shapi[INVESTIGATOR_24126], Lustberg MB. Stoppi[INVESTIGATOR_180251] a previous infusion hypersensitivity reaction. Support Care Cancer. 2015;23(7):2019-24. Epub 2014/12/19. doi: 10.1007/s00520- 014-2556-x. 
PubMed PMID: 25519756; PMCID: PMC4804339. 26. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front- line chemotherapy for metastatic breast cancer: an intergroup trial (E11 93). J Clin Oncol. 
Protocol #: OSU [ZIP_CODE]  
 Version 10/17/2024   
Page 42 of 42  2003;21(4):588-92. Epub 2003/02/15. doi: 10.1200/JCO.2003.08.013. PubMed PMID: 
12586793. 27. Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist. 2001;[ADDRESS_212100] 3:30-5. Epub 2001/05/11. PubMed PMID: 11346683. 28. Symmans WF, Volm MD, Shapi[INVESTIGATOR_180252], Perkins AB, Kim AY, Demaria S, Yee HT, McMullen H, Oratz R, Klein P, Formenti SC, Muggia F. Paclitaxel-induced apoptosis and mitotic arrest assessed by [CONTACT_180280]- needle aspi[INVESTIGATOR_1516]: implications for early prediction of 
breast cancer response to neoadjuvant treatment. Clin Cancer Res. 2000;6(12):4610- 7. Epub 
2001/01/13. PubMed PMID: 11156210. 29. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapi[INVESTIGATOR_24126], Ungaro P, Norton L, Winer E, Hudis C. Randomized phase III trial of weekly compared with every -3-weeks paclitaxel for metastatic breast cancer, w ith 
trastuzumab for all HER -2 overexpressors and random assignment to trastuzumab or not in 
HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008;26(10):1642-9. Epub 2008/04/01. doi: 10.1200/JCO.2007.11.6699. PubMed PMID: 18375893. 30. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, 
Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005;23(25):5983-92. Epub 2005/08/10. doi: 10.1200/JCO.2005.06.232. PubMed PMID: 16087943. 31. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Jr., Wood WC, Davidson NE. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358(16):1663-71. Epub 2008/04/19. doi: 10.1056/NEJMoa0707056. PubMed PMID: 18420499; PMCID: PMC2743943. 32. Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn KJ, Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, Lew DL, Gralow JR, Hortobagyi GN. SWOG S0221: a phase III trial comparing chemotherapy schedules in high- risk early -stage breast cancer. J Clin Oncol. 
2015;33(1):58-64. doi: 10.1200/JCO.2014.56.3296. PubMed PMID: 25422488; PMCID: PMC4268253.  